If anyone is planning on having an MRI with contrast, here are a few recent papers published on the subject
March 2019, Nephrology and Hypertension:
Gadolinium-based contrast agents: why nephrologists need to be concerned
‘Nephrogenic’ systemic fibrosis is mediated by myeloid C-C chemokine receptor 2
The Need for National Guidance Around Informed Consent About GBCA Safety
May 2019, Investigative Radiology:
Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases With Reduced Kinetic Stability of the Agent
Toxicological assessment of anthropogenic Gadolinium in seawater
July 2019, Toxicology and Applied Pharmacology (currently on preview):
Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors
March 2019, Nephrology and Hypertension:
Gadolinium-based contrast agents: why nephrologists need to be concerned
- “Gadolinium-based contrast agents, regardless of their chemical composition, are not eliminated according to a pure two compartment model; every brand seeps into slow-release compartments such as the blood brain barrier (and gadolinium has been found within the nuclei of central nervous system neurons).”
- “Gadolinium is retained in vital organs… Therefore, it’s not surprising that people with gadolinium retention present with a wide range of symptoms.”
‘Nephrogenic’ systemic fibrosis is mediated by myeloid C-C chemokine receptor 2
- “Numerous symptoms that constitute the diagnostic criteria for ‘nephrogenic’ systemic fibrosis are occurring in gadolinium-exposed patients with normal renal function.”
- “Gadolinium-based contrast agents induce recruitment of bone marrow-derived cells to affected organs”
The Need for National Guidance Around Informed Consent About GBCA Safety
- “The research protocol under discussion highlights where the [National Institutes of Health] Roadmap around [gadolinium-based contrast agents] falls short,”
May 2019, Investigative Radiology:
Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases With Reduced Kinetic Stability of the Agent
- “After much uncertainty as to whether [gadolinium-based contrast agents] cause cellular toxicity, we now provide the first definitive evidence that these agents do indeed induce mitochondrial toxicity and cell death in cultured human neurons,”
- “For all GBCAs, cell death increased with exposure dose…” [If you're doctor tells you they'll be using the "Safe kind", they are lying. All I had was the"safe kind" & my gadolinium levels are still elevated 1 year after last injection]
Toxicological assessment of anthropogenic Gadolinium in seawater
- “exposure to Gd strongly affected the biochemical performance…including the decrease on mussels' metabolism, induction of oxidative stress and neurotoxicity”
July 2019, Toxicology and Applied Pharmacology (currently on preview):
Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors
- “Gadolinium-based contrast agent treatment leads to dyslipidemia”
- “Gadolinium-based contrast agents impair renal function, induce pathologic damage, and increase kidney fibrosis.”
Last edited: